Improved overall survival in patients developing endocrine toxicity during treatment with nivolumab for advanced non-small cell lung cancer in a prospective study.
Endocrine toxicity
Hypothyroidism
NSCLC
Nivolumab
Overall survival
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
29 Apr 2024
29 Apr 2024
Historique:
received:
19
07
2023
accepted:
01
12
2023
medline:
29
4
2024
pubmed:
29
4
2024
entrez:
29
4
2024
Statut:
aheadofprint
Résumé
Immune checkpoint inhibitors (ICPIs) disrupting PD-1/PD-L1 axis have revolutionized the management of advanced non-small cell lung cancer (NSCLC). Some studies identified the development of endocrine toxicity as predictor of better survival in cancer patients treated with ICPIs. The aim of study was to evaluate survival and new onset of immune-related endocrine adverse events (irAEs) in patients treated with nivolumab for advanced NSCLC. In a prospective study, 73 patients with previously treated advanced NSCLC received nivolumab in monotherapy. Blood samples were collected at each cycle to monitor thyroid autoimmunity, thyroid, adrenal and somatotroph axes, while thyroid morphology was evaluated by ultrasonography. An impaired thyroid function was recorded in 23.4% of patients (n = 15). Eight patients developed asymptomatic transient thyrotoxicosis (ATT) evolving to hypothyroidism in 50% of cases. In addition, seven patients developed overt hypothyroidism without ATT and with negative autoantibodies. Patients who developed hypothyroidism proved to have better overall survival (OS) as compared with non-developers at both univariate (p = 0.021) and multivariate analyses (p = 0.023). The survival curve of patients with reduced IGF-I at baseline, or displaying its reduction during the follow-up, showed significantly reduced median survival compared to patients with normal/high IGF-I levels (p = 0.031). Thyroid function abnormalities are the major irAEs in patients treated with nivolumab, and hypothyroidism onset is associated with prolonged survival. Our findings indicate that the development of hypothyroidism is a positive predictive biomarker of nivolumab antitumor efficacy in patients with NSCLC. Low IGF-I levels could represent a negative prognostic factor during nivolumab therapy.
Identifiants
pubmed: 38683497
doi: 10.1007/s40618-023-02268-0
pii: 10.1007/s40618-023-02268-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministero dell'Istruzione, dell'Università e della Ricerca
ID : FIRB RBAP11884M
Informations de copyright
© 2024. The Author(s).
Références
Cheung YM, Wang W, McGregor B et al (2022) Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. Cancer Immunol Immunother 71(8):1795–1812. https://doi.org/10.1007/s00262-021-03128-7
doi: 10.1007/s00262-021-03128-7
pubmed: 35022907
pmcid: 9276851
De Miguel M, Calvo E (2020) Clinical challenges of immune checkpoint inhibitors. Cancer Cell 38(3):326–333. https://doi.org/10.1016/j.ccell.2020.07.004
doi: 10.1016/j.ccell.2020.07.004
pubmed: 32750319
Albertelli M, Dotto A, Nista F et al (2021) Present and future of immunotherapy in neuroendocrine tumors. Rev Endocr Metab Disord 22(3):615–636. https://doi.org/10.1007/s11154-021-09647-z
doi: 10.1007/s11154-021-09647-z
pubmed: 33851319
pmcid: 8346388
Melosky B, Juergens R, Hirsh V et al (2020) Amplifying outcomes: checkpoint inhibitor combinations in first-line non-small cell lung cancer. Oncologist 25(1):64–77. https://doi.org/10.1634/theoncologist.2019-0027
doi: 10.1634/theoncologist.2019-0027
pubmed: 31138727
Fanciulli G, Di Molfetta S, Dotto A et al (2020) Emerging therapies in pheochromocytoma and paraganglioma: immune checkpoint inhibitors in the starting blocks. J Clin Med 10(1):88. https://doi.org/10.3390/jcm10010088
doi: 10.3390/jcm10010088
pubmed: 33383673
pmcid: 7795591
Di Molfetta S, Dotto A, Fanciulli G et al (2021) Immune checkpoint inhibitors: new weapons against medullary thyroid cancer? Front Endocrinol (Lausanne) 12:667784. https://doi.org/10.3389/fendo.2021.667784
doi: 10.3389/fendo.2021.667784
pubmed: 33935977
FDA prescribing information (2018). https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125554s058lbl.pdf Accessed 19 May 2021
Guo L, Zhang H, Chen B (2017) Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor. J Cancer 8(3):410–416. https://doi.org/10.7150/jca.17144
doi: 10.7150/jca.17144
pubmed: 28261342
pmcid: 5332892
Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627–1639. https://doi.org/10.1056/NEJMoa1507643
doi: 10.1056/NEJMoa1507643
pubmed: 26412456
pmcid: 5705936
Brahmer J, Reckamp KL, Baas P et al (2013) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123–135. https://doi.org/10.1056/NEJMoa1504627
doi: 10.1056/NEJMoa1504627
Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723. https://doi.org/10.1056/NEJMoa1003466
doi: 10.1056/NEJMoa1003466
pubmed: 20525992
pmcid: 3549297
Ryder M, Callahan M, Postow MA, Wolchok J, Fagin AJ (2014) Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Related Cancer 21(2):371–381. https://doi.org/10.1530/ERC-13-0499
doi: 10.1530/ERC-13-0499
Barroso-Sousa R, Barry WT, Garrido-Castro AC et al (2018) Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 4(2):173–182. https://doi.org/10.1001/jamaoncol.2017.3064
doi: 10.1001/jamaoncol.2017.3064
pubmed: 28973656
Osorio JC, Ni A, Chaft JE et al (2017) Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28(3):583–589. https://doi.org/10.1093/annonc/mdw640
doi: 10.1093/annonc/mdw640
pubmed: 27998967
Kotwal A, Kottschade L, Ryder M (2020) PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients. Thyroid 30(2):177–184. https://doi.org/10.1089/thy.2019.0250
doi: 10.1089/thy.2019.0250
pubmed: 31813343
pmcid: 7047075
Teulings HE, Limpens J, Jansen SN et al (2015) Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Endocrinol Metab 33(7):773–781. https://doi.org/10.1200/JCO.2014.57.4756
doi: 10.1200/JCO.2014.57.4756
Haratani K, Hayashi H, Chiba Y et al (2018) Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 4(3):374–378. https://doi.org/10.1001/jamaoncol.2017.2925
doi: 10.1001/jamaoncol.2017.2925
pubmed: 28975219
Masuda K, Shoji H, Nagashima K et al (2019) Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. BMC Cancer 19(1):974. https://doi.org/10.1186/s12885-019-6150-y
doi: 10.1186/s12885-019-6150-y
pubmed: 31638948
pmcid: 6805586
Ricciuti B, Genova C, De Giglio A et al (2019) Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol 145(2):479–485. https://doi.org/10.1007/s00432-018-2805-3
doi: 10.1007/s00432-018-2805-3
pubmed: 30506406
Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133. https://doi.org/10.1089/thy.2015.0020
doi: 10.1089/thy.2015.0020
pubmed: 26462967
pmcid: 4739132
Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F (2013) Endocrine side effetcs induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 98(4):1361–1375. https://doi.org/10.1210/jc.2012-4075
doi: 10.1210/jc.2012-4075
pubmed: 23471977
Weber JS, Hodi FS, Wolchok JD et al (2017) Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 35(7):785–792. https://doi.org/10.1200/JCO.2015.66.1389
doi: 10.1200/JCO.2015.66.1389
pubmed: 28068177
De Velasco G, Je Y, Bossé D et al (2017) Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. Cancer Immunol Res 5(4):312–318. https://doi.org/10.1158/2326-6066
doi: 10.1158/2326-6066
pubmed: 28246107
pmcid: 5418853
Kumar V, Ghaudhary N, Garg M, Floudas CS, Soni P, Chandra AB (2017) Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol 8:49. https://doi.org/10.3389/fphar.2017.00049
doi: 10.3389/fphar.2017.00049
pubmed: 28228726
pmcid: 5296331
Ramos-Levi AM, Rogado J, Sanchez-Torres JM, Colomer R, Marazuela M (2018) Nivolumab-induced thyroid dysfunction in patients with lung cancer. Endocrinol Diabetes Nutrición 66(1):26–34. https://doi.org/10.1016/j.endinu.2018.05.005
doi: 10.1016/j.endinu.2018.05.005
Brilli L, Danielli R, Ciuoli C et al (2018) Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab. Endocrine 58(3):534–541. https://doi.org/10.1007/s12020-017-1289-2
doi: 10.1007/s12020-017-1289-2
Illouz F, Drui D, Caron P, Do Cao C (2018) Expert opinion on thyroid complications in immunotherapy. Ann Endocrinol (Paris) 79(5):555–561. https://doi.org/10.1016/j.ando.2018.07.007 . (Epub 2018 Jul 25)
doi: 10.1016/j.ando.2018.07.007
pubmed: 30126627
Yamauchi I, Sakane Y, Fukuda Y et al (2017) Clinical features of nivolumab-induced thyroiditis: a case series study. Thyroid 27(7):849–901. https://doi.org/10.1089/thy.2016.0562
doi: 10.1089/thy.2016.0562
Kitajima K, Ashida K, Wada N et al (2017) Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab. Jpn J Clin Oncol 47(5):463–466. https://doi.org/10.1093/jjco/hyx018
doi: 10.1093/jjco/hyx018
pubmed: 28334791
Takaya K, Sonoda M, Fuchigami A, Hiyoshi T (2017) Isolated adrenocorticotropic hormone deficiency caused by nivolumab in a patient with metastatic lung cancer. Intern Med 56(18):2463–2469. https://doi.org/10.2169/internalmedicine.8548-16
doi: 10.2169/internalmedicine.8548-16
pubmed: 28824067
pmcid: 5643175
Zeng MF, Chen LL, Ye HY et al (2017) Primary hypothyroidism and isolated ACTH deficiency induced by nivolumab therapy: case report and review. Medicine 96(44):e8426. https://doi.org/10.1097/MD.0000000000008426
doi: 10.1097/MD.0000000000008426
pubmed: 29095280
pmcid: 5682799
Ariyasu H, Inaba H, Ota T et al (2018) Thyrotoxicosis and adrenocortical hormone deficiency during immune-checkpoint inhibitor treatment for malignant melanoma. In Vivo 32(2):345–351. https://doi.org/10.21873/invivo.11244
doi: 10.21873/invivo.11244
pubmed: 29475919
pmcid: 5905204
Kitano S, Tatsuno K, Ishibe J et al (2018) Isolated adrenocorticotropic hormone deficiency in melanoma patients treated with nivolumab. Acta Derm Venereol 98(7):704–705. https://doi.org/10.2340/00015555-2902
doi: 10.2340/00015555-2902
pubmed: 29405244
Takebayashi K, Ujiie A, Kubo M et al (2018) Isolated adrenocorticotropic hormone deficiency and severe hypercalcemia after destructive thyroiditis in a patient on nivolumab therapy with a malignant melanoma. J Clin Med Res 10(4):358–362. https://doi.org/10.14740/jocmr3257w
doi: 10.14740/jocmr3257w
pubmed: 29511426
pmcid: 5827922
Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X (1999) Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91(2):151–156 ((PMID: 9923856))
doi: 10.1093/jnci/91.2.151
pubmed: 9923856
Spitz MR, Barnett MJ, Goodman GE, Thornuist MD, Wu X, Pollak M (2002) Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort. Cancer Epidemiol Biomark Prev 11(11):1413–1418 ((PMID:12433720))
Wang Z, Wang Z, Liang Z et al (2013) Expression and clinical significance of IGF-1, IGFBP-3, and IGFBP-7 in serum and lung cancer tissues from patients with non-small cell lung cancer. OncoTargets Ther 6:1437–1444. https://doi.org/10.2147/OTT.S51997
doi: 10.2147/OTT.S51997
Gao Y, Katki H, Graubard B et al (2012) Serum IGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma. Int J Cancer 131(2):105–113. https://doi.org/10.1002/ijc.26438
doi: 10.1002/ijc.26438
Christopoulos PF, Msaouel P, Koutsilieris M (2015) The role of the insulin-like growth factor-1 system in breast cancer. Mol Cancer 14:43. https://doi.org/10.1186/s12943-015-0291-7
doi: 10.1186/s12943-015-0291-7
pubmed: 25743390
pmcid: 4335664
Zhang M, Li X, Zhang X, Yang Y, Feng Z, Liu X (2014) Association of serum hemoglobin A1c, C-peptide and insulin-like growth factor-1 levels with the occurrence and development of lung cancer. Mol Clin Oncol 2($):506–508. https://doi.org/10.3892/mco.2014.289
doi: 10.3892/mco.2014.289
pubmed: 24940485
pmcid: 4051575
Boschetti M, Larizza D, Calcaterra V et al (2009) Effect of environment on growth: auxological and hormonal parameters in African and Italian children. Growth Horm IGF Res 19(3):238–241. https://doi.org/10.1016/j.ghir.2008.10.005
doi: 10.1016/j.ghir.2008.10.005
pubmed: 19062321
Heald AH, Sharma R, Anderson SG et al (2005) Dietary intake and the insulin-like growth factor system: effects of migration in two related populations in India and Britain with markedly different dietary intake. Public Health Nutr 8(6):620–627. https://doi.org/10.1079/PHN2005729
doi: 10.1079/PHN2005729
pubmed: 16236191
Peters S, Cappuzzo F, Horn L et al (2017) Analysis of early survival in patients with advanced non-squamous NSCLC treated with nivolumab vs docetaxel in checkmate 057. J Thorac Oncol 12(1):S253. https://doi.org/10.1016/j.jtho.2016.11.241
doi: 10.1016/j.jtho.2016.11.241
Tas F, Karabulut S, Bilgin E, Tastekin D, Duranyildiz D (2014) Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer. Tumour Biol 35(9):9303–9309. https://doi.org/10.1007/s13277-014-2224-2
doi: 10.1007/s13277-014-2224-2
pubmed: 24943688
Feng X, Lin J, Xing S, Liu W, Zhang G (2017) Higher IGFBP-1 to IGF-1 serum ratio predicts unfavourable survival in patients with nasopharyngeal carcinoma. BMC Cancer 17(1):90. https://doi.org/10.1186/s12885-017-3068-0
doi: 10.1186/s12885-017-3068-0
pubmed: 28143425
pmcid: 5286734
Yao Y, Mao W, Dong M, Yang D, Li W, Chen Y (2017) Serum insulin-like growth factor-1 (IGF-1): a novel prognostic factor for early recurrence of hepatocellular carcinoma (HCC). Clin Lab 63(2):261–270. https://doi.org/10.7754/Clin.Lab.2016.160732
doi: 10.7754/Clin.Lab.2016.160732
pubmed: 28182337
Zhao Z, Wang X, Qu J et al (2021) Immune-related adverse events associated with outcomes in patients with NSCLC treated with anti-PD-1 Inhibitors: a systematic review and meta-analysis. Front Oncol 11:708195. https://doi.org/10.3389/fonc.2021.708195
doi: 10.3389/fonc.2021.708195
pubmed: 34604047
pmcid: 8479111
Yamauchi I, Yasoda A, Matsumoto S et al (2019) Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. PLoS ONE 14(5):e0216954. https://doi.org/10.1371/journal.pone.0216954
doi: 10.1371/journal.pone.0216954
pubmed: 31086392
pmcid: 6516638
Baldini E, Lunghi A, Cortesi E et al (2020) Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program. Lung Cancer 140:59–64. https://doi.org/10.1016/j.lungcan.2019.12.014
doi: 10.1016/j.lungcan.2019.12.014
pubmed: 31881412
Campredon P, Mouly C, Lusque A et al (2019) Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients. Presse Med 48(4):e199–e207. https://doi.org/10.1016/j.lpm.2018.10.019
doi: 10.1016/j.lpm.2018.10.019
pubmed: 31005502
Sbardella E, Tenuta M, Sirgiovanni G et al (2019) Thyroid disorders in programmed death-1 inhibitors treated patients: is previous therapy with tyrosine Kinase Inhibitors a predisposing factor? Clin Endocrinol (Oxford) 92(3):258–265. https://doi.org/10.1111/cen.14135
doi: 10.1111/cen.14135
Ksienski D, Wai ES, Croteau N, Lesperance M et al (2019) Efficacy of Nivolumab and Pembrolizumab in patients with advanced non-small-cell lung cancer needing treatment interruption because of adverse events: a retrospective multicenter analysis. Clin Lung Cancer 20(1):e97–e106. https://doi.org/10.1016/j.cllc.2018.09.005
doi: 10.1016/j.cllc.2018.09.005
pubmed: 30337270
Peiró I, Palmero R, Iglesias P et al (2019) Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes. Endocrine 64(3):605–613. https://doi.org/10.1007/s12020-019-01871-7
doi: 10.1007/s12020-019-01871-7
pubmed: 30805887
Barlesi F, Dixmier A, Debieuvre D et al (2020) Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study. Oncoimmunology 9(1):1744898. https://doi.org/10.1080/2162402X.2020.1744898
doi: 10.1080/2162402X.2020.1744898
pubmed: 33457089
pmcid: 7790497
Hosoya K, Fujimoto D, Morimoto T et al (2020) Association between early immune-related adverse events and clinical outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors. Clin Lung Cancer 21(4):e315–e328. https://doi.org/10.1016/j.cllc.2020.01.003
doi: 10.1016/j.cllc.2020.01.003
pubmed: 32113737
Sato K, Akamatsu H, Murakami E et al (2018) Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer 115:71–74. https://doi.org/10.1016/j.lungcan.2017.11.019
doi: 10.1016/j.lungcan.2017.11.019
pubmed: 29290265
Kim HI, Kim M, Lee SH et al (2017) Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer. Oncoimmunology 7(1):e1375642. https://doi.org/10.1080/2162402X.2017.1375642
doi: 10.1080/2162402X.2017.1375642
pubmed: 29296533
pmcid: 5739550